Hypothalamic Obesity
Setmelanotide leads to significant decrease in BMI for patients with hypothalamic obesity
A group of children and adults with hypothalamic obesity receiving setmelanotide for 1 year had nearly a 20% greater BMI reduction than those receiving placebo, according to top-line results released by Rhythm Pharmaceuticals.
Top in endocrinology: Setmelanotide reduces BMI; dangers of endocrine-disrupting chemicals
Results of a phase 2 trial showed that 89% of children and adults with hypothalamic obesity had a 5% or greater reduction in BMI after receiving setmelanotide over 16 weeks.
Setmelanotide lowers BMI by 5% or more for most people with hypothalamic obesity
Setmelanotide reduced BMI by at least 5% at 16 weeks among 89% of children and adults with hypothalamic obesity, according to findings from a phase 2 trial published in The Lancet Diabetes & Endocrinology.
Significant weight loss among patients with hypothalamic obesity seen with setmelanotide
SAN DIEGO — Treatment with the melanocortin-4 receptor agonist setmelanotide was associated with significant weight loss among patients with hypothalamic obesity, according to a presenter at ObesityWeek.
FDA grants breakthrough therapy designation to setmelanotide for hypothalamic obesity
The FDA has granted breakthrough therapy designation to setmelanotide for patients with hypothalamic obesity, according to a company press release.
FDA grants orphan drug designation for hypothalamic obesity treatment
The FDA granted orphan drug designation for an investigational combination therapy for the treatment of hypothalamic obesity, according to an industry press release.